The report provides a detailed analysis essential for establishing a Carfilzomib production plant. It encompasses all critical aspects necessary for Carfilzomib production, including the cost of Carfilzomib production, Carfilzomib plant cost, Carfilzomib production costs, and the overall Carfilzomib production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a Carfilzomib production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Carfilzomib is a medication used to treat blood cancer called multiple myeloma. It is specifically for patients whose cancer has come back or has not responded to previous treatments after they have already received one to three lines of therapy. Carfilzomib is usually given together with two other drugs, lenalidomide and dexamethasone, to enhance its effectiveness. It is a protease inhibitor used either on its own or in combination with chemotherapy.
The procurement of Carfilzomib is influenced by its application in the pharmaceutical and medical industries as an anticancer medication used to treat multiple myeloma or blood cancer. The demand for Carfilzomib is also increasing due to the rising cases of blood cancer. Both when used alone and in conjunction with other antimyeloma treatments (such as dexamethasone), Carfilzomib produced excellent responses in terms of overall survival (OS), progression-free survival (PFS), and response rate.
Numerous finished and ongoing trials supported its acceptable safety profile and its noticeably lower incidence of neuropathy when compared to other drugs of its class. Overall, the industrial Carfilzomib procurement is influenced by its application in the pharmaceutical and medical industries as an anticancer medication, its use with other chemotherapy drugs, excellent clinical research results, fewer side effects, better tolerability, increasing healthcare awareness, technological advancements, and regulatory approvals.
Raw Material for Carfilzomib Production
According to the Carfilzomib production plant project report, the key raw material used in the production of Carfilzomib includes phenylalanine methyl ester.
Production Process of Carfilzomib
The extensive Carfilzomib production cost report consists of the following major industrial production process:
- Production from phenylalanine methyl ester: The production process of Carfilzomib starts with the amide coupling of phenylalanine methyl ester and N-Boc leucine to form a dipeptide intermediate. In the next step, the amine-protecting group is subjected to acid removal and subsequently undergoes a second amide coupling reaction with N-Boc homophenyl alanine to provide a tripeptide intermediate. This intermediate is again subjected to acid removal of the amine-protecting group and is acylated with chloroacetyl chloride, yielding β-chloro amide. The amide is further reacted with morpholine in the presence of potassium iodide in catalytic amounts. The methyl ester undergoes saponification with lithium hydroxide to form an acid intermediate. Finally, the acid intermediate is subjected to amide coupling with keto-epoxyamine using Hydroxybenzotriazole (HOBt) as the coupling reagent. The product thus formed is recrystallized to produce Carfilzomib.
Carfilzomib, commercially known as Kyprolis, is a white to off-white powder, having the molecular formula C40H57N5O7 and a molecular weight of 719.9099 g/mol. It has a log P value of 3.21, and the value of its dissociation constant, pKa, is 11.91. It dissolves in DMSO and ethanol, is very little soluble in acidic conditions, but is almost insoluble in water. Carfilzomib functions as a proteasome inhibitor by binding to the active sites of the 20S proteasome irreversibly. It is used to treat blood cancer called multiple myeloma.
